Vernier Mathieu, Giguère Vincent
Goodman Cancer Research Centre, McGill University, Quebec, Montreal, Canada.
Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec, Montreal, Canada.
J Mol Endocrinol. 2021 Jan;66(1):R1-R14. doi: 10.1530/JME-20-0196.
Aging is a degenerative process that results from the accumulation of cellular and tissue lesions, leading progressively to organ dysfunction and death. Although the biological basis of human aging remains unclear, a large amount of data points to deregulated mitochondrial function as a central regulator of this process. Mounting years of research on aging support the notion that the engendered age-related decline of mitochondria is associated with alterations in key pathways that regulate mitochondrial biology. Particularly, several studies in the last decade have emphasized the importance of the estrogen-related receptor (ERR) family of nuclear receptors, master regulators of mitochondrial function, and their transcriptional coactivators PGC-1s in this context. In this review, we summarize key discoveries implicating the PGC-1/ERR axis in age-associated mitochondrial deregulation and tissue dysfunction. Also, we highlight the pharmacological potential of targeting the PGC-1/ERR axis to alleviate the onset of aging and its adverse effects.
衰老是一个退行性过程,它由细胞和组织损伤的积累导致,逐渐导致器官功能障碍和死亡。尽管人类衰老的生物学基础尚不清楚,但大量数据表明线粒体功能失调是这一过程的核心调节因素。多年来对衰老的研究支持这样一种观点,即线粒体随年龄增长而出现的衰退与调节线粒体生物学的关键途径的改变有关。特别是,过去十年的几项研究强调了核受体雌激素相关受体(ERR)家族、线粒体功能的主要调节因子及其转录共激活因子PGC-1s在这方面的重要性。在这篇综述中,我们总结了涉及PGC-1/ERR轴在与年龄相关的线粒体失调和组织功能障碍中的关键发现。此外,我们强调了靶向PGC-1/ERR轴以减轻衰老及其不良影响的药理学潜力。